Market Data
Market Cap₹3.98 Cr.
52W High₹2.08
Current Price₹2.08
52W Low₹1.57
Face Value₹10
Performance
ROCE-14.1 %
ROE-1,485.71 %
EPS (TTM)₹-0.12
EPS Prev Qtr₹-0.19
EPS Last Year₹-0.12
EBITDA Qtr₹-0.24 Cr.
Financial Health
Debt/Equity107.43
Debt/Profit-7.23
Total Assets₹8.48 Cr.
Promoter Holding35.89 %
Earning Power-12.97 %
Valuation
Industry P/E32.65
Price to Book56.79
Key Metrics
__derived
1
Face Value
₹10
About MPS Pharmaa Ltd
Healthcare · Pharmaceuticals
MPS Pharmaa Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹3.98 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.11 | ₹4,36,678.96 Cr | 0.88% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 84.22 | ₹2,46,407.94 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 76.59 | ₹1,82,633.63 Cr | 0.79% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 25.93 | ₹1,16,044.61 Cr | 0.09% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 32.34 | ₹1,09,059.12 Cr | 0.96% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 97.81 | ₹1,07,055.86 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 50.62 | ₹1,03,455.49 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 31.95 | ₹1,03,165.93 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.04 | ₹95,886.73 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.48 | ₹93,366.88 Cr | 0.88% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.26 | ₹65,185.56 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.52 | ₹61,528.15 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 109.12 | ₹60,461.65 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.73 | ₹57,690.58 Cr | 1.75% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Ipca Laboratories Ltd | - | 36.26 | ₹48,896.41 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.64 | ₹48,298.98 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.39 | ₹47,904.29 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.63 | ₹46,884.81 Cr | 2.06% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.82 | ₹45,194.84 Cr | 0.77% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Profit fell 9.1% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 |
| ↳ QoQ Growth | - | - | - | - | - |
| Expenses | 0.23 | 0.23 | 0.23 | 0.4 | 0.24 |
| Operating Profit | -0.23 | -0.23 | -0.23 | -0.4 | -0.24 |
| OPM % | - | - | - | - | - |
| Other Income | 0 | 0 | 0 | 0.04 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 |
| EBITDA | -0.2 | -0.19 | -0.19 | -0.36 | -0.2 |
| EBITDA Margin % | - | - | - | - | - |
| Profit Before Tax | -0.23 | -0.23 | -0.23 | -0.37 | -0.24 |
| Tax % | 4.35% | 4.35% | 4.35% | 2.7% | 0% |
| Net Profit | -0.22 | -0.22 | -0.22 | -0.36 | -0.24 |
| ↳ QoQ Growth | - | 0.0% | 0.0% | -63.6% | +33.3% |
| EPS | -0.11 | -0.12 | -0.12 | -0.19 | -0.12 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 0 | 0 |
| Expenses | 1.09 | 1.1 |
| Operating Profit | -1.09 | -1.1 |
| OPM % | - | - |
| Other Income | 0.04 | 0.04 |
| Interest | 0 | 0 |
| Depreciation | 0.15 | 0.16 |
| Profit Before Tax | -1.06 | -1.07 |
| Tax % | 3.77% | 2.8% |
| Net Profit | -1.02 | -1.04 |
| EPS | -0.54 | -0.55 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
0%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
-96.23%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 19.1114 | 19.11 |
| Reserves | -18.030684 | -19.04 |
| Borrowings | 7.46 | 7.52 |
| Other Liabilities | 0.79 | 0.89 |
| Total Liabilities | 9.331931 | 8.48 |
| Fixed Assets | 3.8332365 | 3.66 |
| CWIP | 2.9113355 | 2.41 |
| Investments | 0.54 | 0.54 |
| Other Assets | 2.05 | 1.87 |
| Total Assets | 9.331931 | 8.48 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -0.5699447 |
| Cash from Investing Activity | 0.3833912 |
| Cash from Financing Activity | 0.1832728 |
| Net Cash Flow | -0.0032807 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | - |
| ROCE % | -113.54% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 35.89% | 35.89% | 35.89% | 35.89% |
| FIIs % | 0% | 0% | 0% | 0% |
| DIIs % | 0.58% | 0.58% | 0.58% | 0.58% |
| Public % | 37.11% | 37.12% | 37.94% | 37.94% |
| No. of Shareholders | 4,433 | 4,425 | 4,419 | 4,409 |